Universal Definition of Myocardial Infarction
The term myocardialinfarction has major psychological and legal implications for the individual and society. It is an indicator of one of the leading health problems in the world, and it is an outcome measure in clinical trials and observational studies. With these perspectives, MI may be defined from a number of differentclinical, ECG, biochemical, imaging, and pathological characteristics (Table 1 ). This includes a typical rise and fall of Tn with ≥1 value above the 99th percentile of the upper reference limit and ≥1 of the following: clinical symptoms suggestive of ischemia, ECG changes, a new wall-motion abnormality on echocardiography, or new loss of viable myocardium on a nuclear scan. Based on the pathophysiology, MI has been classified into 5 different types, 5 as shown in Table 2 . This same task force also defined the ECG criteria for ischemia (tables 3 and 4) . The newer definition of acute MI as proposed by joint committee was an attempt to improve accuracy in diagnosis of acute MI. However, each component in this definition also has certain limitations. 
Symptoms
Not every patient with acute MI has typical symptoms as described above. The atypical symptoms include (but are not limited to) mental confusion, weakness, not feeling well, syncope, apprehension, and nervousness. Elderly, female, diabetic, and demented patients are likely to present with atypical symptoms. 6 
Electrocardiographic
Apart from acute MI, there are multiple other causes of ST-segment elevation (Table 5 ). These include early repolarization, left bundle branch block (LBBB), preexcitation, Brugada syndrome, pericarditis, myocarditis, pulmonary embolism, subarachnoid hemorrhage (SAH), lead transposition, cholecystitis, prior MI with Q waves and/or persistent ST elevation (left ventricular aneurysm), and a ventricular paced rhythm. 5 cardiac troponin (cTn) complex is made of Tn I (inhibitory), Tn C (calcium-binding), and Tn T (tropomycin-binding) proteins. Myocardial necrosis is signified by increased level of cTn.Cardiac troponin I (cTnI), in particular, is not expressed by injured or regenerating skeletal muscle, and is, therefore, exquisitely specific for myocardial injury. 8 In general, cTnI and cTnT provide comparable information, except in renal failure, where cTnT is more likely to be elevated. 9 Troponin elevation after myocardial necrosis occurs within 2-3 hours, reaches its peak in 24 hours, and remains elevated for 1 to 2 weeks. A multicenter study determining levels of TnI in 1818 consecutive patients with suspected acute MI upon admission and 3 hours and 6 hours after admission has found that 87% of patients with MI could be diagnosed if Tn levels were drawn within 6 hours, whereas the rate of diagnosis was almost 100% when these levels were drawn within 12 hours of presentation. The same study concluded that use of a sensitive assay for cTnI improves early diagnosis of acute MI and risk stratification, regardless of the time of chest-pain onset. 10 The high-sensitivity Tn assay is a very good screening test for myocardial injury, but the enhanced sensitivity results in many Tn elevations, and each of these requires careful clinical consideration. There have been multiple assays for cTnI, but only one CTnT assay. Currently, high-sensitivity assays are recommended.
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The joint ESC/ACC Committee for the Redefinition of Myocardial Infarction has defined MI as an increased cTn exceeding the 99th percentile of the distribution of cTnI in the reference group for that particular assay, with an imprecision limit of ≤10%. A recently published study determined that lowering the diagnostic threshold of Tn for diagnosis of MI could reduce morbidity and mortality 12 ; however, the biggest challenge of lowering the diagnostic threshold of Tn for MI would be a greater number of patients with elevated cTn, including those due to nonthrombotic causes.
Frequency of Troponin Elevation in the Real World
With implementation of high-sensitivity Tn assays, there has been a substantial rise in the incidence of MI diagnosis. 13 -15 In fact, some centers reported a 100% increase in the incidence of MI since Tn measurement became the standard of care. 14 Many studies have described the presence of increased Tn levels in various cardiac and noncardiac conditions, in the absence of definite evidence to support a diagnosis of acute coronary syndrome (ACS). 16 -27 A recently published study evaluated the incidence and type of acute MI in 2944 consecutive patients with cTnI measurement in a tertiary center. Fewer than one-third had acute MI, whereas more than two-thirds of the patients with an elevated cTnI had a non-MI cause of Tn increase. They did find that cTnI levels were higher in patients with acute MI. 28 
Clinical Significance of Troponin Elevation in Absence of Acute Coronary Syndrome
The prevalence and determinant of chronic cTnT elevation was studied in a large, representative population consisting of 3557 subjects of the Dallas Heart Study. They concluded that cTnT elevation was associated with older age, black race, male sex, congestive heart failure, left ventricular hypertrophy, diabetes mellitus, and chronic kidney disease. In the general population, cTnT elevation is a rare in subjects without congestive heart failure, left ventricular hypertrophy, chronic kidney disease, or diabetes mellitus. 29 Most of the studies have shown that Tn release in heart failure (HF) occurs with and without obstructive epicardial coronary disease. 30 When applying the results of Tn testing to acutecare medicine, the major differential diagnosis involves differentiating type 1, type 2, and non-MITn elevation. There are multiple causes of non-MI elevation of troponin (Table 6) . 5,12 -23,31 -33 The postulated mechanisms involved in type 2 MI are listed in Table 2 . These include mismatch between myocardial oxygen demand and supply in the absence of flow-limiting epicardial stenosis. 18, 34 Likewise, the proposed causes for non-MITn increase include imbalance of the autonomic nervous system, with resulting excess of sympathetic activity and increased catecholamine effect on myocardial cells 35 ; direct myocardial-cell injury by traumatic or inflammatory process; volume and pressure overload, resulting in an excessive increase in wall tension with secondary myofibrillary damage 36 ; and impaired renal excretion. 37 In addition, cardiomyocyte damage from inflammatory cytokines or oxidative stress, hibernating myocardium, or apoptosis may produce an elevated Tn. 36,38 -41 Cardiac troponin I release occurs frequently after subarachnoid hemorrhage (SAH) and has been associated with a neurogenic form of myocardial injury. It is primarily due to sympathetic overactivity leading to myocardial necrosis. 42 This overactivity of the sympathetic limb of the autonomic nervous system is a common phenomenon that leads to myocardial necrosis in neurological catastrophes such as SAH, cerebral infarction, status epilepticus, and head trauma. The prognostic significance and clinical impact of elevations of cTnI after SAH was assessed in a study of 253 patients. The study concluded that cTnI elevation after SAH is associated with an increased risk of cardiopulmonary complications, delayed cerebral ischemia, and death or poor functional outcome at discharge. 17, 43 Troponin elevation has also been reported in diabetic ketoacidosis. Metabolic derangement, fluid shifts, tachycardia, and increased sympathetic tone may trigger focal myocardial necrosis and Tn release. Acidosis also contributes in Tn release. 44 With sepsis, TNF-α and mediators produced by neutrophilic granulocytes may lead to anincreased permeability of the cardiomyocyte membrane formacromolecules and therefore leakage of Tn withoutmyocyte necrosis. 45 Elevated cTnI has been associated with increased mortality in patients with 46 -48 and without 17, 49 ACS. Troponin elevation is a mortality risk factor for medical intensive care unit (ICU) patients admitted forreasons other than ACS. Mortality has been reported to be 4-fold higher and left ventricular ejection fraction significantly lower in Tnpositive patients without ACS as compared with Tn-negative critically ill patients. 13 Elevated cTn levels are commonly observed in the ICU. There are many non-ACS causes of cTn elevation in the ICU. 22, 50 The clinical significance of elevated cTn level in patients in the ICU has been reviewed. In one study, the frequency of cTn elevation and its association with mortality and length of ICU stay in 58 consecutive critically ill patients without ACS was reviewed. This study concluded that elevated cTn measurements are associated with increased mortality and ICU length of stay. 51 Accumulating evidence suggests that patients with acute and chronic HF may have measurable levels of circulating cTn, whose detection and magnitude may have prognostic implications. Furthermore, as new, more sensitive cTn assays are being developed, larger numbers of HF patients are found to have detectable cTn, with a persistent relationship between magnitude and outcome. 30 An elevated Tn level in HF correlates with advanced disease and acute decompensation and indicates worst prognosis. 30 It is very important for clinicians to understand that an elevated Tn level is a relatively common finding in hospitalized patients. Although Tn elevation is an essential requirement for the diagnosis of MI, it is not sufficient without confirmation, either by ECG, clinical history, or a new echocardiographic or nuclear finding. There have been a few studies that assessed the possible variables that could predict diagnosis of ACS. The predictors that can help rule in or rule out the diagnosis of ACS in the presence of an elevated Tn level are age, hypertension, and history of ischemic heart disease, renal function, and a maximal cTn level. 52 These predictors can increase diagnostic accuracy and guide the appropriate treatment.The high early and late mortality rate among the patients with non-ACScTn elevation indicates that Tn level serves as an indicator of a critical state in a noncardiac condition.
17

Approach to Increased Troponin: Potential Treatment Strategies
The assessment of whether a Tn elevation is aresult of ACS or non-ACS eventhas become a major challenge and has great implications for both in-hospital and long-term management. Thesituation is more complicated in critically ill patients, where the history is usually limited and the diagnosis is based on objective laboratory and imaging testresults, such as Tn elevation and ECG changes. In some cases, a misdiagnosis of AMI that is only based on the elevated Tn levelmay lead to inappropriate and sometimes harmful management, such as antithrombotic therapy inthe presence of bleeding or a coronary angiogram in thepresence of renal failure. A slight elevation in Tn level is common in hospitalized patientswithin a large spectrum of clinical settings.It is very important for clinicians to develop a systemic approach to cTn elevation. Even if we have a diagnostic test for ACS with a known excellent sensitivity and specificity, we should not ignore the pretest probability of coronary artery disease. age 40-70 years, history of hypertension or ischemic heart disease, normal renal function, anda cTn level >1 ng/mL favors ACS, extreme age (<40 y, >80 y) and impaired renal function favors non-ACScTn elevation. 52 A diagnosis of MI requires combination of clinical history, ECG changes, Tn increase, and/or a new wall-motion abnormality on echocardiogram or nuclear scan showing new loss of viable myocardium. A Tn elevation should be divided into ACS and non-ACS based on clinical history and available diagnostic tools. If probability of ACS is low, then the abovementioned predictors should be considered to proceed with appropriate treatment (see algorithm; Figure 1) . Type 2 MI (demand ischemia) should also be differentiated from noncardiac causes of cTn elevation. This type of MI is the result of an imbalance between myocardial oxygen requirement and supply. Non-ACSTn elevation is due to myocardial injury resulting from variety of mechanisms, such as sympathetic overactivity in SAH or the effect of different inflammatory markers in HF and sepsis.
In conclusion, an elevated Tn level is a relatively common finding in hospitalized patients. Although cTn elevation is an essential requirement forthe diagnosis of MI, it is not sufficient alone. Clinicians must incorporate sound clinical reasoning before making a diagnosis of ACS based on elevated cTn. Patients with cTn elevation unrelated to ACS define a high-riskgroup with poor short-term (in-hospital) and long-term (30 mo from discharge) outcomes.Troponin should not be used as a screening test in patients with a low pretest probability for coronary artery disease, as this approach may leadto inappropriate diagnosis, treatment, and interventions.
